INmune Bio Inc. Common stock (INMB) is a publicly traded Healthcare sector company. As of October 14, 2026, INMB trades at $1.72 with a market cap of $49.40M and a P/E ratio of -0.99. INMB moved +0.00% today. Year to date, INMB is +9.09%; over the trailing twelve months it is -8.20%. Its 52-week range spans $1.09 to $11.64. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces INMB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
1 analysts cover INMB: 0 strong buy, 1 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $8.00.
| Metric | Value |
|---|---|
| Price | $1.72 |
| Market Cap | $49.40M |
| P/E Ratio | -0.99 |
| EPS | $-1.86 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.64 |
| 52-Week Low | $1.09 |
| Volume | 94.99K |
| Avg Volume | 0 |
| Revenue (TTM) | $50.00K |
| Net Income | $-45.93M |
| Gross Margin | 0.00% |
1 analysts cover INMB: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.